| 000 | 01717 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513191812.0 | ||
| 264 | 0 | _c19991123 | |
| 008 | 199911s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1046/j.1365-2036.1999.00581.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCalleja, J L | |
| 245 | 0 | 0 |
_aSustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cSep 1999 |
||
| 300 |
_a1179-86 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 |
_aCryoglobulinemia _xblood |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHepacivirus _ximmunology |
| 650 | 0 | 4 |
_aHepatitis C _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 |
_aLiver _xvirology |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRNA, Viral _xisolation & purification |
| 650 | 0 | 4 |
_aRibavirin _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aAlbillos, A | |
| 700 | 1 | _aMoreno-Otero, R | |
| 700 | 1 | _aRossi, I | |
| 700 | 1 | _aCacho, G | |
| 700 | 1 | _aDomper, F | |
| 700 | 1 | _aYebra, M | |
| 700 | 1 | _aEscartÃn, P | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 13 _gno. 9 _gp. 1179-86 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2036.1999.00581.x _zAvailable from publisher's website |
| 999 |
_c10426220 _d10426220 |
||